Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter International Inc. (NYSE:BAX) has announced a conference call scheduled for April 27, 2023, at 7:30 a.m. Central Time to discuss its first-quarter 2023 financial results. Participants can pre-register for the call via the provided link or access it through Baxter's website. The call will be recorded and copyrighted by Baxter, with restrictions on rebroadcasting without permission. Baxter is recognized for its extensive portfolio in diagnostic, critical care, kidney care, nutrition, and surgical products, emphasizing its commitment to innovation and patient care over the past 90 years.
Baxter International Inc. (NYSE:BAX) has launched ZOSYN (piperacillin and tazobactam) Injection in the U.S., expanding its anti-infective portfolio. The ZOSYN premix is designed to treat various infections and is packaged in Baxter’s proprietary Galaxy containers, ensuring patient safety by simplifying medication preparation and improving operational efficiency. Available in multiple dosages (2.25 g, 3.375 g, and 4.5 g), this ready-to-use formulation aims to reduce contamination risks. Baxter emphasizes that ZOSYN is a significant addition, addressing critical healthcare needs while advancing patient care.
Baxter International Inc. (NYSE:BAX) introduced several innovative surgical solutions at the AORN Global Surgical Conference & Expo 2023 held from April 1-4, 2023. Key products include a new conductive Patient Warming System that minimizes risks linked to forced air warming and is designed to maintain body temperature effectively. The Helux Pro Connected Surgical Light enhances visibility during procedures with deep cavity lighting and a 4K camera. Additionally, the Floseal + Recothrom hemostat, utilizing recombinant thrombin, offers a faster preparation time and eliminates reliance on human blood products. These advancements aim to enhance patient care and efficiency in surgical settings.
Baxter International Inc. (NYSE:BAX) will hold its 2023 Annual Meeting of Stockholders virtually on May 2, 2023, at 9 a.m. Central Time. Online access begins at 8:30 a.m.. Stockholders are encouraged to vote their shares beforehand through proxy materials as in-person attendance is not allowed. Questions can be submitted in advance from April 28 to May 1 or live during the meeting. Those wishing to join as guests can listen-only, without voting or asking questions. Baxter emphasizes its long-standing commitment to innovation in healthcare, serving millions worldwide.
Baxter International Inc. (NYSE:BAX) declared a quarterly cash dividend of $0.29 per share, payable on April 3, 2023, to shareholders of record as of February 24, 2023. This indicates an annual dividend rate of $1.16 per share. The company has a rich history of over 90 years in providing healthcare solutions across more than 100 countries. This dividend declaration reflects Baxter's commitment to returning value to its shareholders amidst a stable operational strategy.
Baxter International reported a Q4 2022 sales increase of 11% to $3.9 billion, with 18% growth for the full year at $15.1 billion. Fourth-quarter U.S. GAAP diluted EPS was $0.36, adjusted EPS $0.88. Full-year U.S. GAAP diluted loss per share was ($4.83), adjusted EPS at $3.50, down 3% year-over-year. The company faces ongoing macroeconomic challenges, leading to plans for a spinoff of its Renal Care and Acute Therapies businesses. Baxter’s cost reduction initiatives aim to save over $300 million in 2023, with a workforce reduction of less than 5%.
Baxter International Inc. (NYSE:BAX) will hold a conference call on February 9, 2023, at 7:30 a.m. Central Time to discuss its fourth-quarter 2022 financial results. Interested participants can pre-register through the provided link or access the call via Baxter’s website. The call will also be recorded for future reference. Baxter continues to be a leader in healthcare with a diverse portfolio including critical care, kidney care, and surgical products utilized globally. For more insights, visit www.baxter.com.
Baxter International Inc. (NYSE:BAX) has announced plans to spin off its Renal Care and Acute Therapies units into a publicly traded company within 12-18 months. This restructuring aims to simplify operations, enhance strategic focus, and improve long-term performance. Additionally, Baxter will explore strategic alternatives for its BioPharma Solutions business to optimize its capital structure. The proposed changes are designed to strengthen Baxter's market position and foster innovation, with sales for the renal unit in 2021 reaching $5 billion.
Summary not available.
The ExactaMix Pro Automated Compounder from Baxter International (NYSE:BAX), set for release in early 2023, enhances security and user experience while offering superior data reporting capabilities. It will be showcased at the ASHP Midyear Clinical Meeting from Dec. 4-8, 2022. This advanced system is certified to the FDA-recognized UL 2900-2-1 cybersecurity standard and provides features designed for increased efficiency and ease of use, including touchscreen responsiveness and 15 months of data storage. ExactaMix Pro signals a significant advancement in compounding technology.